Literature DB >> 32354649

Significance of recanalization of sinuses and resolution of parenchymal lesion in cerebral venous sinus thrombosis.

Varun K Singh1, Neeraj Jain2, Jayantee Kalita3, Usha K Misra4, Sunil Kumar2.   

Abstract

In cerebral venous sinus thrombosis (CVST), the degree of recanalization may determine resolution of parenchymal lesion and clinical outcome. The aim of our study was to evaluate the relationship of recanalization with resolution of MRI lesion and clinical outcome. The patients with CVST diagnosed on the basis of magnetic resonance venography (MRV) were included prospectively. Risk factors, clinical features, and MRI and MRV findings were noted. MRI and MRV were repeated at 6 months and the change in parenchymal lesion and grade of recanalization (I, II, III) were noted. Patients were evaluated clinically at three and six months. Complete recovery was considered if modified Rankin Scale (mRS) score was 0. Thirty-three CVST patients were included, 12 (36.4%) of whom were females. Recanalization occurred in 29 (87.9%), which was complete (grade III) in 6 (21%). Sigmoid sinus (52%) recanalized more frequently. Resolution of parenchymal lesion on repeat MRI occurred in 13.3% (4/30) patients, and they had no sequelae. Degree of recanalization was not related to resolution of neurological sequelae, MRI lesion at follow up and burden of thrombosis at baseline. Varying degree of recanalization occurred in 87.9% patients with CVST, and resolution of parenchymal lesion occurred in 13.3%. Clinical outcome however was not related to recanalization.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cerebral venous thrombosis; MR venography; MRI; Outcome; Recanalization; Sequelae

Year:  2020        PMID: 32354649     DOI: 10.1016/j.jocn.2020.04.112

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  1 in total

1.  Chronic intracranial hypertension after cerebral venous and sinus thrombosis - frequency and risk factors.

Authors:  Christina Geisbüsch; Christian Herweh; Christoph Gumbinger; Peter A Ringleb; Markus A Möhlenbruch; Simon Nagel
Journal:  Neurol Res Pract       Date:  2021-05-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.